CD8A and neoplasm: Our data supported that the combination CN133 with anti-PD-1 can circumvent the resistance to anti-PD-1 treatment by expansion of CD8 + T cells and inhibition of PMN-MDSCs in the soft tissue TME of subcutaneous PCa model, but not showing significantly anti-tumor activity in bone metastatic PCa.